All the biologics for cancer. Promptly.

Prompt Therapeutics is making cancer drug development a high throughput process.

Our platforms assess combinations of targets and therapeutic formats at an unprecedented rate.

We screen millions of these combinations to find all the effective ways to treat cancer with biologics.

Then we develop therapeutics in the optimal weaponized format for each target.

Technology

Prompt's technology platforms combine to map all the surface targets on authentic tumor cells, and then identify all the ways these targets can be drugged effectively by antibody-based therapeutics.

NEST™

NEST generates an unbiased map of cancer cell surface proteins and their isoforms. This approach identifies novel targets exposed through unexpected features of cancer biology.

These targets enable diverse therapeutic assets, including ADC, CD3 engager, CAR-T, radioantibodies, and other formats.

Armory™

Armory matches candidate targets to therapeutic formats to find all combinations with potential to drive killing of tumor cells.

Through massively parallel screening, Armory can identify all targets suitable for addressing with each therapeutic format.

Advantages

Comprehensive: all the ways to treat cancer with biologic therapeutics
Differentiated: novel mechanisms and novel targets in high throughput
Rapid: accelerated generation of de-risked Development Candidates

Partnering

Prompt partners with industry leaders seeking to maximize the value of their therapeutic platforms. From identifying all targets suitable for a particular therapeutic mechanism, to finding unique targets on cells of interest, partnering with Prompt can help advance your goals.

To start a conversation: contact@prompttherapeutics.com

Page updated

Report abuse